Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Summary

This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Acute Coronary Syndrome

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

45 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

DalCor Pharmaceuticals

Last updated on ClinicalTrials.gov

June 22, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites